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Cancers affect the head and neck region frequently and
involve the skin, mucosal surfaces, sinuses, salivary glands,
and endocrine system. There is a wide survival rate
depending on the disease entity but melanoma, advanced
thyroid cancers, and head and neck squamous cell carci-
noma (HNSCC) still cause significant morbidity and mortal-
ity. Melanoma accounts for a minority of the cancers at 4%
but causes a majority of skin cancer deaths.1 The SEER
database estimates there were over 73,000 new melanomas
diagnosed in the United States in 2015 with 9940 deaths
that year from the disease.1 Stage III and IV melanoma carry
a significant morbidity and mortality with a 5-year survival
rate around 40% and 15%e20% respectively.2 Advanced
thyroid cancer carries a significant morbidity and mortality
as well. Stage IV papillary and follicular thyroid cancer have
a 50% 5-year survival rate while stage IV medullary and
anaplastic thyroid cancer carry grim statistics with survival
rates of 28% and 7%, respectively.2 HNSCC occurs in the oral
cavity, oropharynx, larynx, and hypopharynx is the sixth
most common cancer worldwide and the five-year survival
rates are among the worst of the major cancers. There are
over 35,000 new cases of oral and oropharyngeal squamous
cell carcinomas (OPSCC) diagnosed in the United States
each year, resulting in 12,000 deaths.3 Currently, patients
with locally advanced HNSCC are treated with surgery,
radiotherapy, chemotherapy, and molecular targeted
therapies.4 Despite advances in therapy, the morbidity and
mortality of HNSCC remains high with 50% of these patients
relapse and develop advanced and metastatic disease.
Despite significant improvements in the therapy, the long-
term survival rates in patients with advanced stages have
not significantly increased. Treatment often leads to severe
and permanent functional deficits with a negative impact
on patients’ quality of lives.4 There is a great need for the
development of novel therapies to improve survival of
recurrent and metastatic head and neck cancer (HNC) pa-
tients while limiting treatment-related toxicities. Oncolytic
viruses are targeted agents with the potential to fill this
role for the treatment of HNC patients. Oncolytic viruses
selectively replicate in tumor cells naturally or via deletion
of critical virulence proteins that are required for replica-
tion in normal host tissue. This review will focus on the
oncolytic viruses that have shown promise for the treat-
ment of HNC.
Oncolytic viruses for HNC
Oncolytic virotherapy has been injected intratumorally
and intravenously with excellent safety profiles in multiple
human trials. Head and neck cancers are favorable solid
tumors for both methods, but particularly intratumoral
injection due to the proximity of clinically apparent dis-
ease. Multiple viruses have been used with varying degrees
of success including herpes viruses, reovirus, adenovi-
ruses, measles, vaccinia and a variety of others. There are
many clinical trials studying oncolytic viruses and very few
have demonstrated dose limiting toxicities. Talimogene
laherparepvec (T-VEC, Amgen) has showed promise in
treating head and neck squamous cell carcinoma andmelanoma and was recently approved by the FDA for the
treatment of melanoma.5 It is the first oncolytic virus
approved by the FDA and more are anticipated to follow
this track. H101 is oncolytic adenovirus tested in Phase
IeIII trials and is approved for use by China’s Food and
Drug Administration for the treatment of advanced head
and neck cancers.6Oncolytic herpes viruses
Oncolytic herpes simplex viruses (oHSV) are double-
stranded enveloped DNA viruses with naturally occurring
mutations or are genetically engineered to specifically
replicate in tumor tissue and avoid infection and propaga-
tion in normal cells.7 Wildtype HSV hijack’s the host ma-
chinery for replication which is combatted by
phosphorylation of PKR and downstream phosphorylation of
the translation initiating factor, eIF2a. HSV’s viral protein
ICP 34.5 has 2 important functions allowing it to replicate.
It antagonizes PKR by directly dephosphorylating eIF2a and
down-regulates the immune response by decreasing major
histocompatibility complex II (MHC II) expression. Most
oHSV typically have deletion of ICP 34.5 that effectively
abolishes their ability to replicate in normal cells. Cancer
cells typically have upregulated Ras which inhibits phos-
phorylation of PKR, allowing OV replication.
oHSV have shown anti-tumor efficacy in vitro and in vivo
animal models of head and neck cancers.8e10 In clinical
trials investigating safety of oHSV administered to patients,
no dose-related toxicities were identified.8 However,
complete responses or therapeutic efficacy have rarely
been observed so significant improvements in oHSV therapy
are necessary. Currently there are three HSV-1 derived
oncolytic viruses that are being tested for safety and effi-
cacy in patients with head and neck cancers (Table 1).
HF10 is a naturally occurring mutant form of HSV-1 that
lacks the UL56 protein which regulates cytoplasmic trans-
port and release of virions. It has been tested in a phase Ⅰ
trial of intratumoral injections in multiple tumors including
head and neck SCC, melanoma, skin SCC, and others. The
most common side effects were flu-like symptoms and pain
at the injection site.11 The trial is completing enrollment so
the data is pending. It is now being tested in a phase II trial
in combination with ipilumumab for advanced stage mela-
noma (Table 1).
Another oHSV that is now FDA approved under the name
of Imlygic as of October 2015 is T-VEC (talimogene laher-
parepvec, Amgen; formerly Onco-VEXGM-CSF).5 T-VEC has
deletions of ICP 34.5 and ICP 47 but expresses granulocyte
macrophage colony stimulating factor (GM-CSF). It has un-
dergone extensive testing in clinical trials in head and neck
SCC and melanoma. A phase I/II study added T-VEC to
standard cisplatin and radiation for the treatment of
advanced stage III/IV head and neck squamous cell carci-
noma.8 All patients had post-treatment neck dissections.
Median follow up was 29 months with 100% patient free of
locoregional disease and a disease specific survival of 82.4%
and overall survival rate of 70.5%. Pathologic complete
response in the neck dissections were 100%. It should be
noted that these results must be viewed in caveat that all
patients had a post-treatment neck dissection which is not
86 M.O. Old et al.the standard of care, particularly in those with a complete
response to the therapy.
The agent has impressive results in the treatment of
advanced melanoma in which 16.3% patients had a response
to intra-tumoral injection for over 6 months in comparison
to 2.1% in those not receiving the drug. This led to its
approval by the FDA.5 It is now being tested in multiple
trials (Table 1) for recurrent or metastatic melanoma with
and without ipilumumab (NCT01740297). The phase Ib
portion of the study evaluates the safety of talimogene
laherparepvec in combination with ipilimumab and the
phase II is a randomized study that evaluates the safety and
efficacy of talimogene laherparepvec in combination with
ipilimumab versus ipilumumab alone. A phase Ib/III study of
TVEC in combination with pembrolizumab is in the activa-
tion phases worldwide.12
HSV1716 is an oHSV derived from a deletion in the RL1
gene encoding for ICP 34.5. It has been shown to be safe
with direct intra-tumoral injection into patients with gli-
omas, HNSCC, and melanoma. A current phase I trial
(NCT00931931) is being conducted in relapsed or refractory
non-CNS solid tumors in children and adults. Patients who
respond to one injection will have an option for a second
injection. All data is pending.Oncolytic reovirus (respiratory enteric orphan
virus)
Reovirus is a non-enveloped RNA virus that is ubiquitous
with 100% of adults showing sero-positivity.13 It has long
been an interest in the oncolytic field and has been tested
in many phase I, II, and III trials in head and neck and other
tumors. Normal cells will shut down protein synthesis via an
activated PKR will trigger events that lead to activated
EIF2a. Cancerous cells with mutated or activated Ras have
been shown to be sensitive to reovirus replication andTable 1 Current oncolytic clinical trials for cancers affecting t
ClinicalTrials.gov
ID
Oncolytic agent Combination Phase
NCT02428036 TBI-1401(HF10) (HSV-1) No Phase
NCT02272855 TBI-1401(HF10) (HSV-1) Ipilimumab Phase
NCT00769704 TVEC (HSV-1) No Phase
NCT01368276 TVEC (HSV-1) No Mainte
NCT01740297 TVEC (HSV-1) Ipilimumab Phase
NCT00931931 HSV1716 (HSV-1) No Phase
NCT01166542 Reolysin (Reovirus) Paclitaxel and
Carboplatin
Phase
NCT01846091 MV-NIS (Measles virus) No Phase
NCT01584284 GL-ONC1 (Vaccinia) Cisplatin and
radiation
Phase
NCT00429312 JX-594 (Vaccinia) No Phase
NCT00438009 CVA21 (Coxsackievirus
Type A21)
No Phase
IT, intratumoral; IV, intravenous; SCC: squamous cell carcinoma.killing.14,15 There are 3 different serotypes and type 3
(Dearing) has been the most developed and tested (Onco-
lytics Biotech; Calagary, Canada). The first phase I (REO001)
evaluated the safety of intratumoral injection. There were
no dose limiting toxicities and 61% patients responded to
treatment with only headaches and flu-like symptoms.16,17
A phase I/II trial combed reovirus with a platinum-
taxane doublet regimen in incurable or relapse/metasta-
tic HNC. The responses were impressive and the median
overall survival was 8.9 months.18 This led to a randomized
phase III study (REO 018; NCT01166542) of paclitaxel and
carboplatin with or without reovirus in this patient’s with
platinum e refractory, taxane naı¨ve relapsed or metastatic
HNSCC. The study has completed and the company
announced that 167 patients were enrolled. Locoregional
disease patients treated on the intervention arm showed a
statistically significant progression free and overall survival
benefit versus the control arm (P Z 0.0072, HR Z 0.5460;
PZ 0.0146, HRZ 0.5099 respectively).19 For patients with
metastatic disease (n Z 47), the numbers were not pow-
ered enough to detect a difference in PFS or OS, but they
noted a significant tumor stabilization or shrinkage
(P Z 0.021).
Oncolytic adenoviruses
Adenoviruses were one of the first engineered viruses to be
tested in clinical trials. They are double stranded non-
enveloped DNA viruses that are cytotoxic unmodified. Most
oncolytic viruses contain modifications including the dele-
tion of the p300/cbp-binding or the pRB-binding region of
EA1 resulting in tumor selective replication and oncolysis.
Others have a deletion of the E1B 55 kDa gene resulting in
the loss of p53 degradation conferring specificity to
tumors.20e22 Many have been tested pre-clinically but very
few have been tested in clinical trials except for H101,
Onyx 015 and KH901.he head and neck.
IT
versus IV
Disease
I IT SCC skin Melanoma
II IT Stage IIIB, Stage IIIC, or Stage IV
Unresectable or Metastatic
Malignant Melanoma
III IT Unresectable Stage IIIb, IIIc and IV Disease
nance IT Unresectable Stage IIIb, IIIc and IV Disease
Ib IT Unresectable melanoma
I IT Refractory non-central nervous system
(Non-CNS) solid tumors
III IV Metastatic or recurrent SCC
I IT Recurrent or metastatic SCC
I IV Locally advanced H&N SCC
I/II IT Stage III/IV unresectable melanoma
I IT Stage IV melanoma
The current status of oncolytic viral therapy 87H101 is an E1B-deleted adenovirus used primary via
intratumoral injection with favorable safety profile. It was
found to be safe and effective in Phase I, II and III trials
involving combination of the agent with chemotherapy in
head and neck cancers (Yuan, Xia, Xu).23e25 This led to the
approval of this agent by China’s State Food and Drug
Administration for the treatment of head and neck cancer
in 2005.8 There are currently no US trials with the agent.
Onyx 015 is a E1B-55 kDa deleted virus designed to
replicate and destroy p53-deficient cancer and has been
tested in Phase I and II head and neck trials. A phase II trial
of Onyx 015 evaluated safety and response of OV injected
peritumoral and intratumor in 24 patients. Greater than
50% showed significant tumor response, most pronounced in
p53 mutant tumors.26 It has also been tested as a mouth-
wash for the treatment of premalignant oral dysplasia with
one-third of patients having resolution of their lesions with
a favorable toxicity, feasibility, and safety profiles.27
KH901 selectively replicates in telomerase-positive
tumor cells and expresses GM-CSF. A phase Ⅰ trial of intra-
tumoral administration of this OV in advanced head and
neck cancers demonstrated safety, feasibility, and biologic
activity.28
Oncolytic measles viruses
Measles virus is a single stranded enveloped RNA virus that
has extensive preclinical efficacy with modified versions.29
MV-NIS is one particular virus which is genetically modified
and contains the sodium iodide symporter with good pre-
clinical efficacy in head and neck and anaplastic
carcinoma.30e32 MV-NIS is being studied in a phase Ⅰ trial
(Table 1; NCT0186091) in recurrent or metastatic squamous
cell carcinoma and results are pending.
Other oncolytic viruses
A variety of poxviruses have been studied preclinically but
few have made it to trials for head and neck cancers.
Vaccinia virus is the most clinically-vetted of the poxviruses
as not only did it eradicate small pox but it also has a se-
lective affinity for killing cancer cells. NCT01584284
assessed in a Phase I format the safety of an altered
vaccinia virus (GL-ONC1) in combination with standard of
care cisplatin and radiation for locally advanced SCC. GL-
ONC1 is modified via the deletion of thymidine kinase and
also includes an imageable transgene. The study was
completed in 2015 and final results are pending. It is re-
ported to be well-tolerated at therapeutic dose levels, with
documented evidence of antitumor activity in multiple
solid tumors including HNC.33
JX-594 (Developed by Jennerex and Pexa-Vec, Sillajen,
Busan, Korea) is a vaccinia virus with thymidine kinase
deleted but GM-CSF has been added. A phase Ⅰ trial for
advanced solid tumors including HNC was completed
(NCT00625456) and results are pending. Another phase I/II
trial is ongoing with intratumoral injection of JX-594 in
stage III/IV melanoma patients (NCT00429312), Evidence
from the phase Ⅰ portion demonstrated positive re-
sponses.34 Responses were seen in most patients at both
the injected and non-injected lesions. One patient had apartial response and while another had a complete
response. Response was noted of both injected tumors (in 5
of 7 patients) and at least one non-injected tumor. Efficacy
and gene expression was detected in all patients despite
previous vaccinia vaccination.
Coxsackieviruses (CV) are ubiquitous and typically cause
self-limiting viral upper respiratory infections. CVA21 is a
naturally occurring form of the virus that is being tested in
a phase I trial (NCT00438009) for Stage IV melanoma (Table
1). It is injected intratumorally into superficial lesions.35
CVA21 uses two receptors (intracellular adhesion mole-
cule 1 (ICAM-1) and decay accelerating factor) for infection
which are expressed on melanoma cells as well as other
cancers.Molecular imaging using viruses
Measuring response in clinical trials for oncolytic viral
therapy is done by standard RECIST criteria. However,
incorporating novel imaging techniques into trials is
beginning to occur. It has been described for over the last
15 years that non-invasive and quantitative imaging
assessment of viral-mediated thymidine kinase activity can
be performed using conventional nuclear medicine tech-
nology (e.g., planar GC imaging, SPECT, SPECT/CT and PET/
CT) and a substrate (i.e., 20-fluoro-20-deoxy-1b-D-arabino-
furanosyl-5-iodouracil or FIAU) radiolabeled with Fluorine-
18 (18F, positron-emitter, half-life of w110 m), Iodine-123
(123I, gamma emitter, half-life of 13.2 h), Iodine-124 (124I,
positron-emitter, half-life of w4.2 d), Iodine-125 (125I,
weak gamma emitter, half-life of 60 d) or Iodine-131 (131I,
gamma and therapeutic beta minus emitter, half-life of
w8 d).36e41 Originally developed as an antiviral for herpes
and hepatitis, FIAU is a thymidine nucleoside analog which
is initially phosphorylated by viral thymidine kinases. FIAU-
monophosphate is further phosphorylated into FIAU-
diphosphate and e triphosphate by other intracellular ki-
nases. FIAU-triphosphate becomes incorporated into DNA
and eventually inhibits viral replication.36,38,42,43 Interest-
ingly, mammalian thymidine kinases exhibit very low levels
of FIAU phosphorylation when compared with HSV-1-tk.38
During its initial clinical evaluation as an antiviral ther-
apy for chronic hepatitis B, long-term daily administration
of FIAU lead to lactic acidosis and multi-organ toxicity.44 On
the other hand, single nuclear medicine administration of
radiolabeled FIAU guided by the tracer principle requires a
significantly lower dose (lower by 105e106) for imaging
HSV-1-tk activity.42,45 Tracer doses of 124I-FIAU have already
been used successfully for PET/CT imaging of bacterial
thymidine kinase activity in patients with active musculo-
skeletal infections with no evidence of toxicity.46 Several
pre-clinical studies have demonstrated the utility of FIAU
imaging of intracellular thymidine kinase expression/ac-
tivity and especially for herpes simplex virus 1 thymidine
kinase (HSV-1-tk).36 Depending on the kinetics of the pro-
cess under investigation, PET imaging of HSV-1-tk can be
performed using the shorter-lived 18F-FIAU or the long-lived
124I-FAIU.47 FIAU does not readily penetrate the intact
blood brain barrier (BBB) but can readily localize within the
central nervous system under conditions of BBB disrup-
tion.42 FIAU has been used successfully for imaging HSV-1-tk
88 M.O. Old et al.expression in tumors mediated through various viral vectors
including herpes viral, adenoviral and retroviral vectors.42
In vivo and in vitro, accumulation of FIAU radioactivity
corresponds to virally-infected/transfected viable cells.43
HSV-1-tk activity in tumors can be detected within 30 min
post injection but depending on the radioisotope used, HSV-
1-tk activity can be serially imaged for hours to days
following administration.36,37
The long-lived therapeutic 131I-FIAU agent has been used
pre-clinically to assess the efficacy of oncolytic viral ther-
apy in tumors treated with ganciclovir.38 Furthermore,
bortezomib has been shown to induce thymidine kinase
activity in some viral-associated tumors and this effect can
be detected and monitored using diagnostic radiolabeled
FIAU imaging or further exploited with therapeutic radio-
labeled FIAU.39,41 Advanced molecular imaging approaches
using radiolabeled FIAU will likely prove useful for future
clinical trials that employ existing and new oncolytic viral
agents expressing the HSV-1-tk.37
Future directions
The majority of oncolytic viral research is focused on
combination therapy. OV therapy alone has historically
shown to be effective in preclinical studies but preliminary
clinical trials have shown mixed efficacy. Thus, the field has
moved towards enhancing not only the viral infection but
the host’s response to it. Immunosuppression with chemo-
therapy (cisplatin, bortezomib) or monoclonal antibodies
(cetuximab) has been used in trials with safe side effect
profiles and enhancement of the OV response. Anti-
angiogenic strategies with copper chelation and other
agents is a focus of much research to reduce the influx of
the immune system, antiviral immune response, and wash-
out effect of the virus. Histone deacetylase inhibitors
combined with reovirus has shown significant synergy via
up-regulation of the cell-surface viral receptor as well as
some immune system responses that are being further
defined. An exciting direction of OV therapy is in the field of
immune stimulation with incorporation of endogenous
factors (viral produced GM-CSF) or combination therapy
with checkpoint agents such PD-1 inhibitors. Current trials
are underway and being opened with these combinations
under the theory and preclinical evidence that stimulating
a robust host anti-tumor response will lead to synergy and
enhancement of OV therapy.
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